Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (6): 686-689.

Previous Articles     Next Articles

Study on anti-osteoporosis bioactivity of 2, 3-dihydro-7-methoxy-4h-1-benzopyran-4-isoniazonum in vitro

WANG Jie-pin1,3, SHANG Fu-jun2, XIONG Xiao-yun1, LIU Li1, HOU Jin1, MEI Qi-bing1   

  1. 1Department of Pharmacology, School of Pharmacy, Fourth Millitary Medical University, Xi ' an 710032, Shaanxi,China;
    2Department of Cardiology, Tangdu Hospital, Fourth Millitary Medical University, Xi ' an 710038, Shaanxi,China;
    3Institute of Materia Medica, School of Pharmacy, Fourth Millitary Medical University, Xi ' an 710032,Shaanxi, China
  • Received:2007-03-01 Revised:2007-04-25 Published:2020-11-09

PDF (PC)

85

Abstract: AIM:From early studies an anti-osteoporosis compound I (2, 3-dihydro-7-methoxy-4h-1-benzopyran-4-isoniazonum) was screened and here to discuss its bioactivity in vitro.METHODS: Compared with estrodiol (E2), the cell proliferation, alkaline phosphatase (ALP) activity and osteocalcin (OCN) secretion as indexes to determine the effects of this compound on proliferation and differentiation of osteoblast cell line MC3T3-E1.RESULTS:The best dose of compound I was 10-6 mol/L. At this concentration, compound I could significantly increase the number of osteoblast cells, elevate ALP activity and OCN secretion (125. 73%, 108. 49% 109. 00% vs control, P<0. 05). All these effects could be blocked by introducing of the antieatrogen tamoxifen.CONCLUSION:Compound I has the ability in treating osteoporosis, whose mechanism maybe relate to estrogen agonist.

Key words: MC3T3-E1 cells, MTT, alkaline phosphatase activities, osteocalcin secretion

CLC Number: